The first volunteer to receive a personalized mRNA-based treatment has completed the full course of therapy, Gazeta.ru reported, citing Alexander Gintsburg, scientific director of Moscow’s Gamaleya Research Institute of Epidemiology and Microbiology.
The patient is now undergoing monthly follow-up examinations using high-resolution computed tomography (CT) scans at the National Medical Research Center for Radiology under the Russian Ministry of Health. The high-resolution scans allow Andrey Kaprin, the center’s head, to examine the patient’s entire body, paying particular attention to his lymph nodes.
According to Gintsburg, about four months have passed since the treatment ended. The man reportedly feels well, and recent examinations have shown no signs of new tumors.
The patient will remain under observation for the next three years.
Gintsburg explained that the drug, developed using mRNA technology, acts as a «tuner» for the immune system. It programs the body’s natural defenses to recognize and destroy malignant tumors and metastases on their own.
However, there is no «universal» cure, as every tumor is unique, the scientist said. The vaccine is manufactured individually, tailored to a specific person’s genetic profile.
Meanwhile, Kazakhstan is also developing its own anti-cancer drug, DVC, with large-scale production planned for mid-2027. According to Sayasat Nurbek, minister of science and higher education, the first phase of the drug’s testing is complete, and specialists are now moving on to the second stage.
